Eli Lilly's Obesity Pill Shows Big Wins In Weight, Blood Sugar And Heart Risk Factors

Eli Lilly and Co. (NYSE:LLY) on Tuesday released topline results from the Phase 3 ATTAIN-2 trial, evaluating oral orforglipron in adults with obesity or overweight and type 2 diabetes.

In the trial, all three doses of orforglipron met the primary and all key secondary endpoints, delivering significant weight loss, meaningful A1C reductions, and improvements in cardiometabolic risk factors at 72 weeks.

With the completion of ATTAIN-2, Lilly now has the complete clinical data package required to initiate global regulatory submissions for orforglipron.

Also Read: Viking Obesity Pill Faces Steep Climb Against Lilly’s Tirzepatide, Analyst Calls Downtrend Reaction’ Extreme’

In the ATTAIN-2 trial, orforglipron met the primary endpoint of superior body weight reduction compared to placebo.

Earlier this month, Eli Lilly stock came under pressure when it released data from Phase 3 ATTAIN-1 trial, showing orforglipron 36 mg lowered weight by an average of 12.4% (27.3 lbs) compared to 0.9% (2.2 lbs) with placebo using the efficacy estimand, below Wall Street’s expectations of around 15%.

Tuesday’s data helped ease some of those concerns, with shares rising nearly 3% in premarket trading.

For the primary endpoint, ...